Pernix Therapeutics Holdings (NYSE:PTX) major shareholder James Edward Jr. Smith sold 45,000 shares of the stock on the open market in a transaction dated Monday, April 7th. The shares were sold at an average price of $4.90, for a total transaction of $220,500.00. Following the sale, the insider now directly owns 4,612,704 shares in the company, valued at approximately $22,602,250. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) shares after opening at $4.81 moved to $5.58 on last trade day and at the end of the day closed at $5.45. Company price to sales ratio in past twelve months was calculated as 2.40 and price to cash ratio as 13.05. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) showed a positive weekly performance of 7.92%.
MEI Pharma, Inc. (NASDAQ:MEIP) announced the presentation of new pre-clinical data showing the ability of its lead drug candidate Pracinostat to inhibit bladder cancer cell growth and induce activated transcription factor 3 (ATF-3) expression, a potential marker of tumor response. The data were presented yesterday at the American Association for Cancer Research (AACR) Annual Meeting in San Diego. MEI Pharma Inc. (NASDAQ:MEIP) shares advanced 8.74% in last trading session and ended the day on $10.08. MEIP return on equity ratio is recorded as -46.50% and its return on assets is -44.30%. MEI Pharma Inc. (NASDAQ:MEIP) yearly performance is 22.48%.
Lannett Company, Inc. logo Lannett Company (NYSE:LCI) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued on Wednesday, American Banking & Market News reports. Lannett Company, Inc. (NYSE:LCI) shares moved up 8.37% in last trading session and was closed at $35.35, while trading in range of $32.95 – $35.37. Lannett Company, Inc. (NYSE:LCI) year to date (YTD) performance is 6.80%.
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced on 31 march the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) weekly performance is -6.58%. On last trading day company shares ended up $39.50. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) distance from 50-day simple moving average (SMA50) is -18.34%. Analysts mean target price for the company is $54.44.
Leave a Reply